CME Presentations
Generalized Myasthenia Gravis (gMG)
Presentations
Applying Enhanced Understanding of the Mechanisms of Disease in Generalized Myasthenia Gravis (gMG): Improved Diagnostics and Targeted Treatment Options
Speakers: James Howard Jr., MD, Professor of Neuromuscular DiseaseNicholas Silvestri, MD, FAAN, Associate Professor of Neurology Duration: 60 minutes
Presented on: March 9, 2021
Speakers
CME Information
Applying Enhanced Understanding of the Mechanisms of Disease in Generalized Myasthenia Gravis (gMG): Improved Diagnostics and Targeted Treatment Options
LEARNING OBJECTIVES
After completing this activity, the participant should be better able to:- Describe the role of pathogenic antibodies in driving the pathophysiology of gMG, their contributions as biomarkers of disease and potential response to therapy, and the need for autoantibody testing
- Describe the burden of gMG disease and the challenges faced by patients who receive traditional treatments
- Describe the MOA, efficacy, safety, and place in therapy of emerging biologic treatments for gMG
- Summarize the correlation between autoantibody status, prediction of therapeutic response, and symptom improvement based on patient-outcome measures
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC working in collaboration with the National Organization for Rare Disorders (NORD), Myasthenia Gravis Foundation of America (MGFA), and the Muscular Dystrophy Association (MDA).ACKNOWLEDGEMENT
Supported by an educational grant from argenx.TUITION
Complimentary
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.LIVE CREDIT DESIGNATION STATEMENT
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ENDURING CREDIT DESIGNATION STATEMENT
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.DATE OF RELEASE/EXPIRATION
Live Activity
Tuesday, March 9, 2021 2:00-3:00pm ESTEnduring Material
March 9, 2021 – March 9, 2022.TARGET AUDIENCE
The intended audience for this activity program are neuromuscular, neuroimmunology, neuro-ophthalmology, and neurology specialists, along with neurology advanced-practice providers.ESTIMATED TIME TO COMPLETE
This activity should take approximately 1 hour to complete.METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to www.NeuroSeriesLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship James F, Howard Jr., MD
Professor of Neuromuscular Disease
Professor of Neurology & Medicine
The University of North Carolina
Chapel Hill, NCConsulting Fees: Argenx BVBA, Alexion Pharm, Ra Pharma (now UCB), Immunovant, Viela Bio
Other: Research Support to my institution: Alexion Pharm, Argenx, BVBA, Pharma (now UCB)Nicholas J. Silvestri MD, FAAN
Associate Professor of Neurology
University at Buffalo Jacobs School of Medicine & Biomedical Sciences
Buffalo, NYConsulting Fees: Alexion, Argenx, Biogen, Immunovant, Sarepta, Strongbridge, UCB
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship Carole Drexel
Medical Director
PlatformQ Health Education, LLCNone
The PIM planners and managers have nothing to disclose.
The following PlatformQ Health Education, LLC planner, Bridget Griffin, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support: Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.
Technical Support: For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive.com at 1-877-394-1306 or at Info@NeuroSeriesLive.com or Support@NeuroSeriesLive.com.